BCL6 and B-cell non-Hodgkin lymphoma: Dysregulation of and dependenceon BCL6 is regularly observed in B-cell lymphomas.3,4 BCL6acts as a transcriptional repressor to a broad range of genes viathe recruitment of corepressors (NCOR, SMRT, or BCOR) to its dimericBTB domain, which enables binding to key sites on DNA.5,6 The protein–protein interaction (PPI) between BCL6 and itscorepressors has been targeted as a potential therapy for BCL6-drivenlymphomas.